MAPT and Alzheimer disease: In recent years, many CSF biomarkers were introduced in the guideline of AD diagnosis, such as Aβ42, total tau (T-tau), and phosphorylated tau (P-tau), and their fluctuation concentration is also conducive to predicting cognitive decline(McKhann et al., 2011; Mutlu et al., 2017).